w/ DARA (.64) the Surgivision IPO will improve the balance sheet significantly. DARA has no debt currently but this will allow them to fuel the clinical trials from other products. They will get an instant non-dilutive cash infusion. DARA will put the money back into their company!
Message in reply to:
Any ideas whether DARA wants to maintain a long-term ownership position in Surgivision or intends to monetize that investment at some point in the future, or intends to spoin off the Surgivision shares to DARA shareholders? The Surgivision IPO will presumably improve book value and the balance sheet overall for DARA but it won't directly impact revenues, earnings or cash
Market Data 
Markets 
AI
